111 related articles for article (PubMed ID: 9766503)
1. A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias.
Park WS; Bae YM; Chung DH; Kim TJ; Choi EY; Chung JK; Lee MC; Park SY; Park MH; Park SH
Leukemia; 1998 Oct; 12(10):1583-90. PubMed ID: 9766503
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia.
Kim TJ; Park SH
J Korean Med Sci; 1998 Oct; 13(5):455-8. PubMed ID: 9811172
[TBL] [Abstract][Full Text] [Related]
3. JL1, a novel differentiation antigen of human cortical thymocyte.
Park SH; Bae YM; Kwon HJ; Kim TJ; Kim J; Lee SJ; Lee SK
J Exp Med; 1993 Oct; 178(4):1447-51. PubMed ID: 8376947
[TBL] [Abstract][Full Text] [Related]
4. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications.
Shin YK; Choi YL; Choi EY; Kim MK; Kook MC; Chung J; Choi YK; Kim HS; Song HG; Park SH
Cancer Immunol Immunother; 2003 Aug; 52(8):506-12. PubMed ID: 12768327
[TBL] [Abstract][Full Text] [Related]
5. Expression of leukemia-associated antigen, JL1, in bone marrow and thymus.
Shin YK; Choi EY; Kim SH; Chung J; Chung DH; Park WS; Jung KC; Kim HS; Park S; Kim HJ; Park MH; Min CK; Kim CC; Park SH
Am J Pathol; 2001 Apr; 158(4):1473-80. PubMed ID: 11290565
[TBL] [Abstract][Full Text] [Related]
6. Expression of JL1 is an effective adjunctive marker of leukemia cutis.
Park YS; Park SH; Park SJ; Kim Y; Jang KT; Ko YH; Lee MW; Huh JR; Park CS
Arch Pathol Lab Med; 2010 Jan; 134(1):95-102. PubMed ID: 20073611
[TBL] [Abstract][Full Text] [Related]
7. JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma.
Kim MS; Park CJ; Cho YU; Jang S; Seo EJ; Park CS; Huh J; Im HJ; Seo JJ; Yoon DH; Suh C
Ann Lab Med; 2020 Jan; 40(1):1-6. PubMed ID: 31432632
[TBL] [Abstract][Full Text] [Related]
8. The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in
Park SH; You E; Park CJ; Jang S; Cho YU; Yoon CH; Koh KN; Im HJ; Seo JJ
Ann Lab Med; 2019 Jul; 39(4):358-366. PubMed ID: 30809981
[TBL] [Abstract][Full Text] [Related]
9. Expression of JL1 in Burkitt lymphoma is associated with improved overall survival.
Hwang I; Go H; Jeon YK; Ko YH; Yoon DH; Suh C; Huh JR; Lee H; Gil M; Park CS
Virchows Arch; 2011 Oct; 459(4):353-9. PubMed ID: 21814778
[TBL] [Abstract][Full Text] [Related]
10. Anti-JL1 antibody-conjugated poly (L-lysine) for targeted gene delivery to leukemia T cells.
Suh W; Chung JK; Park SH; Kim SW
J Control Release; 2001 May; 72(1-3):171-8. PubMed ID: 11389996
[TBL] [Abstract][Full Text] [Related]
11. Identification of antigenic peptide recognized by the anti-JL1 leukemia-specific monoclonal antibody from combinatorial peptide phage display libraries.
Chung J; Park S; Kim D; Rhim J; Kim I; Choi I; Yi K; Ryu S; Suh P; Chung D; Bae Y; Shin Y; Park S
J Cancer Res Clin Oncol; 2002 Dec; 128(12):641-9. PubMed ID: 12474050
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo properties of murine monoclonal antibody for a novel immature thymocyte-differentiated antigen, JL1.
Chung JK; So Y; Hong MK; Choi SR; Jeong JM; Lee DS; Lee MC; Koh CS; Choi EY; Park SH
Nucl Med Biol; 1997 Jul; 24(5):433-7. PubMed ID: 9290079
[TBL] [Abstract][Full Text] [Related]
13. Leukemia-specific siRNA delivery by immunonanoplexes consisting of anti-JL1 minibody conjugated to oligo-9 Arg-peptides.
Lee YK; Kim KS; Kim JS; Baek JE; Park SI; Jeong HY; Yoon SS; Jung KC; Song HG; Park YS
Mol Cells; 2010 May; 29(5):457-62. PubMed ID: 20396968
[TBL] [Abstract][Full Text] [Related]
14. Analysis of peroxidase-negative acute unclassifiable leukemias by monoclonal antibodies. 1. Acute myelogenous leukemia and acute myelomonocytic leukemia.
Imamura N; Tanaka R; Kajihara H; Kuramoto A
Eur J Haematol; 1988 Nov; 41(5):420-8. PubMed ID: 3061835
[TBL] [Abstract][Full Text] [Related]
15. MUC18, a member of the immunoglobulin superfamily, is expressed on bone marrow fibroblasts and a subset of hematological malignancies.
Filshie RJ; Zannettino AC; Makrynikola V; Gronthos S; Henniker AJ; Bendall LJ; Gottlieb DJ; Simmons PJ; Bradstock KF
Leukemia; 1998 Mar; 12(3):414-21. PubMed ID: 9529137
[TBL] [Abstract][Full Text] [Related]
16. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases.
Janossy G; Coustan-Smith E; Campana D
Leukemia; 1989 Mar; 3(3):170-81. PubMed ID: 2465463
[TBL] [Abstract][Full Text] [Related]
17. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.
Lanza F; Bi S; Castoldi G; Goldman JM
Leukemia; 1993 Oct; 7(10):1570-5. PubMed ID: 7692192
[TBL] [Abstract][Full Text] [Related]
18. Migration of acute lymphoblastic leukemia cells into human bone marrow stroma.
Makrynikola V; Bianchi A; Bradstock K; Gottlieb D; Hewson J
Leukemia; 1994 Oct; 8(10):1734-43. PubMed ID: 7523799
[TBL] [Abstract][Full Text] [Related]
19. Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia.
Jeon YK; Min HS; Lee YJ; Kang BH; Kim EJ; Park HJ; Bae Y; Lee HG; Park WS; Song HG; Jung KC; Park SH
Cancer Immunol Immunother; 2011 Dec; 60(12):1697-706. PubMed ID: 21710258
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric analysis of cell-surface and intracellular antigens in the diagnosis of acute leukemia.
Paredes-Aguilera R; Romero-Guzman L; Lopez-Santiago N; Burbano-Ceron L; Camacho-Del Monte O; Nieto-Martinez S
Am J Hematol; 2001 Oct; 68(2):69-74. PubMed ID: 11559944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
